vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and TAYLOR DEVICES, INC. (TAYD). Click either name above to swap in a different company.

Fortress Biotech, Inc. is the larger business by last-quarter revenue ($16.1M vs $11.6M, roughly 1.4× TAYLOR DEVICES, INC.). TAYLOR DEVICES, INC. runs the higher net margin — 17.3% vs -24.5%, a 41.8% gap on every dollar of revenue. On growth, TAYLOR DEVICES, INC. posted the faster year-over-year revenue change (35.7% vs 6.3%). Over the past eight quarters, Fortress Biotech, Inc.'s revenue compounded faster (11.0% CAGR vs -2.7%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Taylor Corporation is a privately owned print and communications company headquartered in North Mankato, Minnesota, and was founded in 1975 by businessman Glen Taylor. The company comprises more than 90 locations and employs nearly 10,000 employees. Taylor has print operations in dozens of U.S. states and multiple countries around the world.

FBIO vs TAYD — Head-to-Head

Bigger by revenue
FBIO
FBIO
1.4× larger
FBIO
$16.1M
$11.6M
TAYD
Growing faster (revenue YoY)
TAYD
TAYD
+29.5% gap
TAYD
35.7%
6.3%
FBIO
Higher net margin
TAYD
TAYD
41.8% more per $
TAYD
17.3%
-24.5%
FBIO
Faster 2-yr revenue CAGR
FBIO
FBIO
Annualised
FBIO
11.0%
-2.7%
TAYD

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
FBIO
FBIO
TAYD
TAYD
Revenue
$16.1M
$11.6M
Net Profit
$-3.9M
$2.0M
Gross Margin
66.1%
47.0%
Operating Margin
-28.8%
19.2%
Net Margin
-24.5%
17.3%
Revenue YoY
6.3%
35.7%
Net Profit YoY
41.8%
90.2%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
TAYD
TAYD
Q4 25
$16.1M
$11.6M
Q3 25
$17.6M
$9.9M
Q2 25
$16.4M
$15.6M
Q1 25
$13.1M
$10.6M
Q4 24
$15.1M
$8.5M
Q3 24
$14.6M
$11.6M
Q2 24
$14.9M
$12.1M
Q1 24
$13.0M
$12.3M
Net Profit
FBIO
FBIO
TAYD
TAYD
Q4 25
$-3.9M
$2.0M
Q3 25
$5.8M
$2.2M
Q2 25
$15.5M
$3.7M
Q1 25
$-10.6M
$2.0M
Q4 24
$-6.8M
$1.1M
Q3 24
$-12.9M
$2.7M
Q2 24
$-10.9M
$2.5M
Q1 24
$-15.4M
$2.7M
Gross Margin
FBIO
FBIO
TAYD
TAYD
Q4 25
66.1%
47.0%
Q3 25
67.4%
44.8%
Q2 25
69.9%
48.6%
Q1 25
63.5%
42.9%
Q4 24
69.1%
45.5%
Q3 24
69.4%
47.4%
Q2 24
61.6%
48.8%
Q1 24
53.9%
46.9%
Operating Margin
FBIO
FBIO
TAYD
TAYD
Q4 25
-28.8%
19.2%
Q3 25
-38.6%
22.6%
Q2 25
-222.2%
24.2%
Q1 25
-169.9%
19.1%
Q4 24
-158.3%
11.0%
Q3 24
-151.0%
25.0%
Q2 24
-186.5%
20.8%
Q1 24
-280.6%
24.4%
Net Margin
FBIO
FBIO
TAYD
TAYD
Q4 25
-24.5%
17.3%
Q3 25
33.2%
22.1%
Q2 25
94.4%
23.7%
Q1 25
-80.6%
19.0%
Q4 24
-44.7%
12.4%
Q3 24
-88.0%
23.0%
Q2 24
-73.5%
20.5%
Q1 24
-118.3%
22.0%
EPS (diluted)
FBIO
FBIO
TAYD
TAYD
Q4 25
$-0.15
Q3 25
$0.11
Q2 25
$0.45
Q1 25
$-0.48
Q4 24
$-0.16
Q3 24
$-0.76
Q2 24
$-0.73
Q1 24
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
TAYD
TAYD
Cash + ST InvestmentsLiquidity on hand
$79.4M
$40.7M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$67.1M
Total Assets
$185.5M
$72.8M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
TAYD
TAYD
Q4 25
$79.4M
$40.7M
Q3 25
$86.2M
$36.3M
Q2 25
$74.4M
$36.0M
Q1 25
$91.3M
$35.4M
Q4 24
$57.3M
$26.6M
Q3 24
$58.9M
$27.1M
Q2 24
$76.2M
$31.0M
Q1 24
$83.8M
$24.6M
Total Debt
FBIO
FBIO
TAYD
TAYD
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
TAYD
TAYD
Q4 25
$49.9M
$67.1M
Q3 25
$55.9M
$64.3M
Q2 25
$43.9M
$62.0M
Q1 25
$22.3M
$57.8M
Q4 24
$22.7M
$55.8M
Q3 24
$21.2M
$53.9M
Q2 24
$17.9M
$51.2M
Q1 24
$23.0M
$47.8M
Total Assets
FBIO
FBIO
TAYD
TAYD
Q4 25
$185.5M
$72.8M
Q3 25
$181.4M
$70.3M
Q2 25
$159.9M
$71.6M
Q1 25
$178.1M
$70.1M
Q4 24
$144.2M
$62.9M
Q3 24
$127.1M
$61.9M
Q2 24
$145.7M
$63.1M
Q1 24
$164.6M
$54.8M
Debt / Equity
FBIO
FBIO
TAYD
TAYD
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
TAYD
TAYD
Operating Cash FlowLast quarter
$-12.5M
$5.7M
Free Cash FlowOCF − Capex
$4.4M
FCF MarginFCF / Revenue
38.3%
Capex IntensityCapex / Revenue
11.3%
Cash ConversionOCF / Net Profit
2.86×
TTM Free Cash FlowTrailing 4 quarters
$14.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
TAYD
TAYD
Q4 25
$-12.5M
$5.7M
Q3 25
$-6.1M
$483.6K
Q2 25
$-27.6M
$1.9M
Q1 25
$-19.6M
$9.0M
Q4 24
$-12.9M
$103.1K
Q3 24
$-20.1M
$-3.6M
Q2 24
$-21.8M
$6.5M
Q1 24
$-25.4M
$-685.0K
Free Cash Flow
FBIO
FBIO
TAYD
TAYD
Q4 25
$4.4M
Q3 25
$298.6K
Q2 25
$491.3K
Q1 25
$8.8M
Q4 24
$-620.5K
Q3 24
$-3.8M
Q2 24
$6.1M
Q1 24
$-895.5K
FCF Margin
FBIO
FBIO
TAYD
TAYD
Q4 25
38.3%
Q3 25
3.0%
Q2 25
3.2%
Q1 25
83.6%
Q4 24
-7.3%
Q3 24
-33.0%
Q2 24
51.0%
Q1 24
-7.3%
Capex Intensity
FBIO
FBIO
TAYD
TAYD
Q4 25
11.3%
Q3 25
1.9%
Q2 25
9.3%
Q1 25
1.8%
Q4 24
8.5%
Q3 24
0.0%
2.1%
Q2 24
3.3%
Q1 24
1.7%
Cash Conversion
FBIO
FBIO
TAYD
TAYD
Q4 25
2.86×
Q3 25
-1.04×
0.22×
Q2 25
-1.78×
0.52×
Q1 25
4.51×
Q4 24
0.10×
Q3 24
-1.35×
Q2 24
2.65×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons